This site is intended only for healthcare professionals resident in the Republic of Ireland




Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up



About CIBINQOEfficacyEfficacyOverviewEfficacy of CIBINQO + Medicated TopicalsEfficacy of CIBINQO Without Medicated TopicalsReduction in Risk of FlaresLong-term Efficacy ResultsBefore and After PhotosGlossarySafetySafetySafety ProfileSafety ConsiderationsLab AbnormalitiesDosing & MonitoringDosing &
DosingLab Monitoring

Click here for CIBINQO Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

Lab MonitoringScreening and lab monitoring with CIBINQO¹

An appropriate CIBINQO patient should meet all of the following:
• Platelets ≥150 × 103/mm3
• Absolute lymphocyte count (ALC) ≥0.5 × 103/mm3
• Absolute neutrophil count (ANC) ≥1.2 × 103/mm3
• Haemoglobin (Hb) ≥10 g/dL

Serious infections:

  • Treatment must not be initiated in patients with an active, serious systemic infection
  • If a patient develops a serious infection, sepsis, or opportunistic infection, dose interruption should be considered until the infection is controlled


  • Use of live, attenuated vaccines should be avoided during or immediately prior to treatment. Prior to initiating treatment with this medicinal product, it is recommended that patients be brought up to date with all immunisations, including prophylactic herpes zoster vaccinations, in agreement with current immunisation guidelines


  • Patients should be screened for tuberculosis (TB) before starting treatment and yearly screening for patients in highly endemic areas for TB should be considered. CIBINQO must not be given to patients with active TB. For patients with a new diagnosis of latent TB or prior untreated latent TB, preventive therapy for latent TB should be started prior to initiation of CIBINQO

Viral reactivation:

  • Screening for viral hepatitis should be performed in accordance with clinical guidelines before starting therapy and during therapy with CIBINQO. Patients with evidence of active hepatitis B or hepatitis C infection were excluded from clinical studies. Patients who had HBV DNA above the lower limit of quantification (LLQ) were excluded. Patients who had HBV DNA negative or below LLQ could initiate treatment; such patients had HBV DNA monitored. If HBV DNA is detected, a liver specialist should be consulted.
  • Viral reactivation, including herpes virus reactivation (e.g. herpes zoster, herpes simplex), was reported in clinical studies (see section 4.8 of the SmPC). The rate of herpes zoster infections was higher in patients who were treated with 200 mg, 65 years of age and older, with a medical history of herpes zoster, with a confirmed ALC < 1 × 103/mm3 prior to the event and patients with severe atopic dermatitis at baseline (see section 4.8 of the SmPC). If a patient develops herpes zoster, temporary interruption of treatment should be considered until the episode resolves. 
Review Lab AbnormalitiesLoading
Explore more Learn More about CIBINQO About CIBINQOLoading Safety Across Clinical Trials

Consistent safety profile in patients with moderate-to severe AD studied across JADE clinical trials

See Safety Profile Loading

Prescribing information

Please see the CIBINQO Summary of Product Characteristics for more information.

Reference:CIBINQO Summary of Product Characteristics.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.

Dosing & Monitoring 
Take On Moderate-to-Severe AD With CIBINQO

Discover the efficacy of CIBINQO

See Efficacy OverviewLoading

Legal Category: S1A
Further information is available upon request

PP-CIB-IRL-0094 June 2023

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit


This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.


Copyright © 2023 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0176. January 2023
For Healthcare Professionals in the Republic of Ireland *

The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.

I confirm that I am a healthcare professional resident in the Republic of Ireland.*

I accept and agree to the terms of use.*

If you select 'No', you will be redirected to, where you will be able to access information on Pfizer Healthcare Ireland.

PP-UNP-IRL-0176. January 2023

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.